RELIEF THERAPEUTICS Holding Ltd.
RLF
ISIN CH1251125998 / Valor 125112599
RELIEF THERAPEUTICS Holding Ltd.
UMushroom community rating:
About company
Relief Therapeutics Holding Ltd. is a Swiss clinical-stage biopharmaceutical company that develops and seeks to commercialize therapies for acute and life‑threatening conditions, with a strategy that emphasizes advancing clinical-stage candidates (including repurposed molecules) through regulatory review and partnering or licensing for commercialization. The company operates with a pipeline focused on severe respiratory and other critical indications, pursues collaboration and licensing deals to fund development and broaden market access, and — as is typical for small-cap biotech firms — generates little or no product revenue while bearing the development and regulatory risks associated with clinical trials and approval processes.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (24.07.2026):
RELIEF THERAPEUTICS Holding Ltd. — Q2 2016 (five-month period ended May 31, 2016): Relief reported income of EUR 3.5 million and a negative EBITDA of EUR 1.4 million for the period. The announcement was made as a non-routine disclosure to allow shareholder Pierrel SpA to deconsolidate Relief following a July 18, 2016 business combination and capital increase; Relief will publish consolidated financial statements for the half-year ended June 30, 2016 on or before September 30, 2016.
Financial results
For the five-months ended May 31, 2016 (reported here as Q2 2016 coverage), Relief generated income of EUR 3.5 million and recorded a negative EBITDA of EUR 1.4 million (from both continuing and discontinued operations).
Reason for non-routine announcement
The disclosure was made to enable Pierrel SpA, a shareholder formerly partially consolidating Relief, to comply with Italian reporting requirements after Pierrel’s stake was diluted by Relief’s July 18, 2016 business combination and capital increase—necessitating Pierrel’s deconsolidation of Relief.
Upcoming reporting
Relief plans to publish its consolidated financial statements for the half-year ended June 30, 2016 on or before September 30, 2016.
Business / pipeline highlights
Relief is a clinical-stage biotechnology company with lead candidates aviptadil (Phase III for sarcoidosis, orphan focus) and low-dose interleukin-6 (atexakin alfa; Phase II for peripheral diabetic neuropathy) — the latter under an exclusive agreement with Merck-Serono. The report cites a peripheral diabetic neuropathy market estimate of $4.1 billion in 2019.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
3 M
Market cap (USD)
1,342,464
Daily traded volume (Shares)
4.59 / 4.26
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
